FluoroPharma Medical, Inc., formerly Commercial E-Waste Management Inc., is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with applications in the area of cardiology. The Company operates through biopharmaceutical research and development segment. It is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)